Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 324

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 324
---
 |
| Balance atDecember 31, 2024                                                   |        2,526 |                        — |           -840 |                      68,185 |                                     5,260 |                    2,376 |                                77,507 |                                     350 |      77,857 |

(a) See Notes D.15.1., D.15.3., D.15.4. and D.15.5. (b) This line comprises the impact of the i ssuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control of EUROAPI . (c) This line includes the use of existing shares to fulfill vested rights under restricted share plans. (d) This line mainly comprises changes in non-controlling interests arising from divestments and acquisitions. (e) This a mount includes the valuation of the shares distributed as a dividend in kind, at a price of € 14.58 per share, as of May 10, 2022 (see Note D.1.3).

| F-8 | SANOFIFORM 20-F2024 |

| 2024CONSOLIDATED FINANCIAL STATEMENTS |
| Consolidated statements of cash flows |

Consolidated statements of cash flows

| (€ million)                                                                                                            | Note                      |   2024 | 2023(a) | 2022(a) |
| Net income attributable to equity holders of Sanofi                                                                    |                           |  5,560 |   5,400 |   8,371 |
| Net (income)/loss from the discontinued Opella business(a)                                                             |                           |    -64 |    -338 |    -401 |
| Non-controlling interests                                                                                              | D.32.                     |     58 |      36 |     113 |
| Share of undistributed earnings from investments accounted for using the equity method                                 |                           |     82 |     293 |     -45 |
| Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets andintangible assets   |                           |  3,586 |   4,429 |   3,108 |
| Gains and losses on disposals of non-current assets, net of tax(b)                                                     |                           |   -366 |    -364 |    -590 |
| Net change in deferred taxes                                                                                           |                           |   -802 |  -1,233 |    -529 |
| Net